Liquidia (LQDA) EBIT Growth (3y) (2023 - 2026)
Liquidia (LQDA) EBIT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Liquidia | 6.40 Bn | 6.12 Bn | 160.92 Mn | 79.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.12% |
| Mar 31, 2026 | 105.37% |
| Dec 31, 2025 | 71.52% |
| Sep 30, 2025 | 30.06% |
| Jun 30, 2025 | -61.10% |
| Mar 31, 2025 | -34.77% |
| Dec 31, 2024 | -47.02% |
| Sep 30, 2024 | -60.35% |
| Jun 30, 2024 | -62.36% |
| Mar 31, 2024 | -47.36% |
| Dec 31, 2023 | -18.43% |
| Sep 30, 2023 | -0.18% |
| Jun 30, 2023 | -18.50% |
| Mar 31, 2023 | 14.26% |